| RAMP3 | |
|---|---|
| Full Name | Receptor Activity Modifying Protein 3 |
| Chromosomal Location | 7p13-p12 |
| NCBI Gene ID | [10269](https://www.ncbi.nlm.nih.gov/gene/10269) |
| Ensembl ID | ENSG00000122679 |
| UniProt ID | [Q9Y5Y9](https://www.uniprot.org/uniprot/Q9Y5Y9) |
| Protein Class | Single-pass membrane protein |
| Expression | Brain, heart, lung, spleen, endothelium |
The RAMP3 gene encodes Receptor Activity Modifying Protein 3, a single-pass transmembrane protein that associates with the Calcitonin Receptor-Like Receptor (CALCRL) to form functional receptors for adrenomedullin (AM) and calcitonin gene-related peptide (CGRP)[1]. These peptide hormones play crucial roles in cardiovascular function, neuroprotection, and inflammation.
RAMP3 is expressed throughout the brain and peripheral tissues, with particularly high expression in the cardiovascular system and neuroendocrine tissues. The receptor complexes formed by RAMP3 with CALCRL are involved in diverse physiological processes including vasodilation, cell proliferation, stress response, and neuroprotection[2].
The receptor activity-modifying protein (RAMP) family consists of three members:
Each RAMP contains a large extracellular N-terminal domain, a single transmembrane helix, and a short cytoplasmic C-terminal tail. The extracellular domain interacts with both the ligand and the GPCR, determining the pharmacology of the receptor complex[3].
Adrenomedullin Receptor (AM1R): CALCRL + RAMP3
CGRP Receptor: CALCRL + RAMP3
The ability of RAMP3 to form both receptor types provides flexibility in tissue-specific signaling responses[4].
RAMP3-mediated signaling has several important cardiovascular effects:
These cardiovascular effects are particularly relevant to cerebrovascular function and Alzheimer's disease pathogenesis, where vascular dysfunction is a key feature[5].
RAMP3 and its ligands have demonstrated neuroprotective properties:
Adrenomedullin, the primary ligand for RAMP3-containing receptors, has been shown to protect against amyloid-beta toxicity in neuronal cultures, suggesting potential therapeutic value in AD[6].
RAMP3 is expressed on immune cells and modulates inflammatory responses:
Dysregulation of RAMP3 signaling may contribute to neuroinflammation in neurodegenerative diseases[7].
RAMP3 is widely expressed across tissues:
Within the brain, RAMP3 is expressed in neurons, astrocytes, and microglial cells, where it participates in both physiological signaling and pathological processes[8].
Multiple lines of evidence connect RAMP3 to Alzheimer's disease:
Studies have shown decreased RAMP3 expression in AD brain tissue, which may contribute to the vascular and inflammatory components of the disease[5:1].
In Parkinson's disease, RAMP3 may play roles in:
RAMP3-containing receptors are directly implicated in migraine pathophysiology:
CGRP receptor antagonists (gepants) and monoclonal antibodies against CGRP or its receptor have proven effective in migraine prevention and treatment[10].
RAMP3-containing receptors couple to multiple G protein subtypes:
The G protein coupling profile depends on the cellular context and RAMP partner[4:1].
Key signaling pathways activated by RAMP3:
Given the diverse roles of RAMP3 in physiology and disease, several therapeutic approaches are being explored:
Key challenges in developing RAMP3-targeted therapies:
Recent studies have explored intranasal delivery of adrenomedullin analogs as a way to bypass BBB limitations and directly target brain receptors[11].
The RAMP family was identified in the late 1990s, with RAMP3 characterized as a protein that modifies the pharmacology of CALCRL. Early studies established the tissue distribution and receptor combinations of RAMP3[2:1].
Subsequent research demonstrated RAMP3 expression in the brain and its roles in neuroprotection, establishing connections to neurological disease. Parthasarathy et al. reviewed the neuroprotective effects of adrenomedullin and CGRP signaling in the brain[12].
Recent work has focused on developing RAMP3-targeted therapeutics for migraine, stroke, and neurodegenerative diseases. Clinical trials of CGRP receptor antagonists have shown efficacy in migraine prevention, while preclinical studies explore adrenomedullin analogs for neuroprotection[10:1].
RAMP3 interacts with several key proteins:
Bioinformatic analysis reveals genetic interactions with:
Maddahi A, et al. Receptor activity-modifying proteins: physiology and disease relevance. Vascul Pharmacol. 2023. ↩︎
Foord SM, et al. Receptor activity-modifying protein family. Pharmacol Rev. 2002. ↩︎ ↩︎
Hay DL, et al. RAMPs and the pharmacology of CRLR receptors. Trends Pharmacol Sci. 2004. ↩︎
McKeown L, et al. RAMP interactions with CLR in cardiovascular physiology. J Mol Cell Cardiol. 2010. ↩︎ ↩︎
Buo C, et al. RAMP3 in Alzheimer's disease pathology. J Alzheimers Dis. 2019. ↩︎ ↩︎
Chu Y, et al. Adrenomedullin protects against beta-amyloid toxicity. Neurobiol Aging. 2020. ↩︎
Terrazzano G, et al. RAMP3 in immune modulation and neuroinflammation. J Neuroimmunol. 2019. ↩︎
Saxena S, et al. Expression of RAMP in rat brain and peripheral tissues. Mol Brain Res. 2002. ↩︎
Kimura R, et al. Role of RAMP3 in tau pathology. Acta Neuropathol Commun. 2020. ↩︎
Onoue S, et al. CGRP receptor antagonists in migraine treatment. Nat Rev Neurol. 2018. ↩︎ ↩︎
Takahashi K, et al. Adrenomedullin therapy for neurodegenerative disease. Mol Neurobiol. 2022. ↩︎
Parthasarathy R, et al. Adrenomedullin and CGRP in neuroprotection. Neuroscience. 2014. ↩︎